Recent advancements in the cardiovascular drug carriers

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 1, 2016, Pages 216-225

  Singh, Baljeet ^a   Garg, Tarun ^a   Goyal, Amit K ^a   Rath, Goutam ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Cardiovascular disease; Gene therapy; Nanoparticle; Nanotechnological approaches

Indexed keywords

CARDIOLOGY; CARDIOVASCULAR SYSTEM; DISEASE CONTROL; DRUG DELIVERY; GENE THERAPY; GENE TRANSFER; NANOPARTICLES;

CARDIO-VASCULAR DISEASE; CELL TRANSPLANTATION; CLINICAL TREATMENTS; NANOTECHNOLOGICAL APPROACHES; PERIPHERAL ARTERIAL DISEASE; POOR STABILITY; SMALL MOLECULES; VASCULAR DISEASE;

DISEASES;

ANTIBODY; CARDIOVASCULAR AGENT; DENDRIMER; LIPOSOME; NANOCARRIER; NANOMATERIAL; DNA; MICELLE; NANOPARTICLE; TABLET;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN; MICELLIZATION; MICROBUBBLE; NONHUMAN; PH; REVIEW; TABLET; ULTRASOUND; CARDIOVASCULAR DISEASES; DEVICES; GENETICS; MICELLE; NANOMEDICINE; PATHOLOGY; PROCEDURES; PULSATILE FLOW; THERAPEUTIC USE; ULTRASOUND THERAPY;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DENDRIMERS; DNA; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; LIPOSOMES; MICELLES; MICROBUBBLES; NANOMEDICINE; NANOPARTICLES; PULSATILE FLOW; TABLETS; ULTRASONIC THERAPY;

EID: 84971659490     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2014.937868     Document Type: Review

References (72)

1. Alwan A. 2011. Global Status Report on Noncommunicable Diseases 2010. Geneva: World Health Organization.
2. Anthea M, Hopkins J, Mclaughlin CW, Johnson S, Warner MQ, Lahart D, Wright JD. 1993. Human Biology and Health. Englewood Cliffs: New Jersey, pp 76-134.
3. Arora N, Bilandi A, Garg T. 2012a. Microneedle: as a future prospective tool. Int Res J Pharm. 3: 102-105.
4. Arora N, Singh K, Garg T. 2012b. Areas of nanomedicine applications. Int J Univ Pharm Life Sci. 2: 216-227.
5. Chang T. 2011. Nanobiotechnology-based blood substitutes and the cardiovascular systems in transfusion medicine. Nanomedicine Cardiovasc Syst. 77-98.
6. Chang TM 2012. From artificial red blood cells, oxygen carriers, and oxygen therapeutics to artificial cells, nanomedicine, and beyond. Artif Cells Blood Substit Immobil Biotechnol. 40: 197-199.
7. Christian DA, Cai S, Bowen DM, Kim Y, Pajerowski JD, Discher DE. 2009. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur J Pharm Biopharm. 71: 463-474.
8. Dantas AP, Jiménez-Altayó F, Vila E. 2012. Vascular aging: facts and factors. Front Physiol. 3: 325.
9. Ding B-S, Dziubla T, Shuvaev W, Muro S, Muzykantov VR. 2006. Advanced drug delivery systems that target the vascular endothelium. Mol Interv. 6: 98.
10. Discher BM, Won Y-Y, Ege DS, Lee JC, Bates FS, Discher DE, Hammer DA. 1999. Polymersomes: tough vesicles made from diblock copolymers. Science. 284: 1143-1146.
11. Fuster V, Kelly BB. 2010 Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health Washington, DC: National Academies Press.
12. Gagandeep GARG, T., Malik B, Rath G, Goyal AK. 2014. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 53: 10-16.
13. Garg T. 2012. An evolutionary approaches in development of needle free injection technologies. Int J Pharm Pharm Sci. 4: 590-596.
14. Garg T. 2014. Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol. 1-8.
15. Garg T, Bilandi A, Kapoor B. 2011a. Scaffold: tissue engineering and regenerative medicine. Int Res J Pharm. 2: 37-42.
16. Garg T, Bilandi A, Kapoor B. 2012a. Evolutionary approaches for drug and gene delivery by micro and nano magnetic carriers. Indo-global Res J Pharm Sci. 2: 182-189.
17. Garg T, Chanana A, Sharma G. 2012b. Pulsatile drug delivery systems: pulsincap system. IOSR J Pharm. 2: 338-339.
18. Garg T, Goyal AK. 2012. Iontophoresis: drug delivery system by applying an electrical potential across the skin. Drug Deliv Lett. 2: 270-280.
19. Garg T, Goyal AK. 2014a. Biomaterial-based scaffolds-current status and future directions. Expert Opin Drug Deliv. 11: 767-789.
20. Garg T, Goyal AK. 2014b. Liposomes: targeted and controlled delivery system. Drug Deliv Lett. 4: 62-71.
21. Garg T, Goyal AK, Arora S, Murthy R. 2012c. Development, optimization and evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of Type-2 diabetes mellitus. Drug Deliv Lett. 2: 251-261.
22. Garg T, Rath G, Goyal AK. 2014. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv.
23. Garg T, Singh O, Arora S, Murthy R. 2011b. Dendrimer - A novel scaffold for drug delivery. Int J Pharm Sci Rev Res. 7: 211-220.
24. Garg T, Singh O, Arora S, Murthy R. 2012d. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 29: 1-63.
25. Garg T, Singh S, Goyal AK. 2013. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst. 30: 369-409.
26. Geiser M, Rothen-Rutishauser B, Kapp N, Schürch S, Kreyling W, Schulz H, et al. 2005. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect. 113: 1555.
27. Goyal AK, Rath G, Garg T. 2013a. Nanotechnological approaches for genetic immunization. In: Erdmann VA and Barciszewski J, eds. DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases Berlin: Springer, pp. 67-120.
28. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. 2013b. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv.
29. Gundogdu E, Senyigit Z, Ilem-Ozdemir D. 2014. Nanomedicine for the diagnosis and treatment of cardiovascular disease: current status and future perspective. Cardiovascr Dis I.
30. Haeri A, Sadeghian S, Rabbani S, Anvari MS, Boroumand MA, Dadashzadeh S. 2011. Use of remote film loading methodology to entrap sirolimus into liposomes: Preparation, characterization and in vivo efficacy for treatment of restenosis. Int J Pharm. 414: 16-27.
31. Huang CC, Liao ZX, Chen DY, Hsiao CW, Chang Y, Sung HW. 2014. Injectable cell constructs fabricated via culture on a thermoresponsive methylcellulose hydrogel system for the treatment of ischemic diseases. Adv Healthc Mater.
32. Ise M, Ise H, Shiba Y, Kobayashi S, Goto M, Takahashi M, et al. 2011. Targeting N-acetylglucosamine-bearing polymer-coated liposomes to vascular smooth muscle cells. J Artif Organs. 14: 301-309.
33. Jagdale SC, Sali MS, Barhate AL, Kuchekar BS, Chabukswar AR. 2013. Formulation, development, and evaluation of floating pulsatile drug delivery system of atenolol. PDA J Pharm Sci Technol. 67: 214-228.
34. Janib SM, Moses AS, Mackay JA. 2010. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 62: 1052-1063.
35. Jeon G, Yang SY, Byun J, Kim JK. 2011. Electrically actuatable smart nanoporous membrane for pulsatile drug release. Nano Lett. 11: 1284-1288.
36. Jordan SW, Chaikof EL. 2007. Novel thromboresistant materials. J Vasc Surg. 45:A104-A115.
37. Jung H, Jang M-K, Nah J-W, Kim Y-B. 2009. Synthesis and characterization of thermosensitive nanoparticles based on PNIPAAm core and chitosan shell structure. Macromol Res. 17: 265-270.
38. Karavas E, Georgarakis E, Bikiaris D. 2006. Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics. Eur J Pharm Biopharm. 64: 115-126.
39. Kataria K, Sharma A, Garg T, Goyal AK, Rath G. 2014. Novel technology to improve drug loading in polymeric nanofibers. Drug Deliv Lett. 4: 79-86.
40. Kaur M, Garg T, Rath G, Goyal AK. 2014a. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 31: 49-88.
41. Kaur M, Malik B, Garg T, Rath G, Goyal AK. 2014b. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv.
42. Kona S, Dong J-F, Liu Y, Tan J, Nguyen KT. 2012. Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. Int J Pharm. 423: 516-524.
43. Lee CC, Mackay JA, Fréchet JM, Szoka FC. 2005. Designing dendrimers for biological applications. Nat Biotechnol. 23: 1517-1526.
44. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. 2013. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380: 2224-2260.
45. Liu Y, Liu S, Dai Q. 2009. Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate. Chem Pharm Bull. 57: 55-60.
46. Magrez A, Kasas S, Salicio V, Pasquier N, Seo JW, Celio M, et al. 2006. Cellular toxicity of carbon-based nanomaterials. Nano Lett. 6: 1121-1125.
47. Mathers C, Fat DM, Boerma J. 2008. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization.
48. Mathers CD, Loncar D. 2006. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3: e442.
49. McGill HC, Mcmahan CA, Gidding SS. 2008. Preventing Heart Disease in the 21st Century Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study. Circulation. 117: 1216-1227.
50. Miyake F, Kamogawa A, Sakakibara M. 1998. [Drug delivery system in cardiovascular drugs]. Nihon Rinsho. 56: 737-741.
51. Mobed M, Chang TM. 1998. Comparison of polymerically stabilized PEG-grafted liposomes and physically adsorbed carboxymethylchitin and carboxymethyl/glycolchitin liposomes for biological applications. Biomaterials. 19: 1167-1177.
52. Moghimi SM, Hunter AC, Murray JC. 2005. Nanomedicine: current status and future prospects. FASEB J. 19: 311-330.
53. Nel A, Xia T, Mädler L, Li N. 2006. Toxic potential of materials at the nanolevel. Science. 311: 622-627.
54. Nishiya T, Chang TM. 1994. Toxicity of liposomes containing low mol% of dienoyl phosphocholine to blood: use of carboxymethyl chitin to reduce toxicity. Artif Cells Blood Substit Immobil Biotechnol. 22: 883-888.
55. Parnami N, Garg T, Rath G, Goyal AK. 2013. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol.
56. Patel SS 2006. Liposome: a versatile platform for targeted delivery of drugs. Pharmainfonet. 5: 1-5.
57. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. 2003. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release. 90: 323-334.
58. Pi F, Tu X, Wu Y. 2010. [Preparation of ATP-2Na loaded liposome and its effect on tissues energy state in myocardial ischemic mice]. Yao Xue Xue Bao, 45: 1322-1326.
59. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, et al. 1998. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 339: 861-867.
60. Sharma G, Garg T. 2012. Importance and application of gene therapy. Int J Institut Pharm Life Sci. 2: 205-220.
61. Shuvaev V V, Dziubla T, Wiewrodt R, Muzykantov VR. 2004. Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies. In: Niemeyer CM, ed. Bioconjugation Protocols. Berlin: Springer.
62. Singh H, Sharma R, Joshi M, Garg T, Goyal AK, Rath G. 2014a. Transmucosal delivery of Docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol.
63. Singh K, Arora N, Garg T. 2012a. RFID: A trustable security tool in pharmaceutical industry. Am J Pharm Tech Res. 2: 113-127.
64. Singh K, Arora N, Garg T. 2012b. Superbug: antimicrobial resistance due to NDM-1. Int J Institut Pharm Life Sci. 2: 58-66.
65. Singh O, Garg T, Rath G, Goyal AK. 2014b. Microbicides for the treatment of sexually transmitted HIV infections. J Pharm. 1-18.
66. Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ. 1998. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model. J Control Release. 54: 201-211.
67. Sutton JT, Haworth KJ, Pyne-Geithman G, Holland CK. 2013. Ultrasound-mediated drug delivery for cardiovascular disease. Expert Opin Drug Deliv. 10: 573-592.
68. Takahama H, Shigematsu H, Asai T, Matsuzaki T, Sanada S, Fu HY, et al. 2013. Liposomal amiodarone augments anti-arrhythmic effects and reduces hemodynamic adverse effects in an ischemia/reperfusion rat model. Cardiovasc Drugs Ther. 27: 125-132.
69. Torchilin VP 2012. Multifunctional nanocarriers. Adv Drug Deliv Rev. 64: 302-315.
70. Wang Y, Chang TM. 2012. Nanobiotechnological nanocapsules containing polyhemoglobin-tyrosinase: effects on murine B16F10 melanoma cell proliferation and attachment. J Skin Cancer. 2012: 673291.
71. Wiewrodt R, Thomas AP, Cipelletti L, Christofidou-Solomidou M, Weitz DA, Feinstein SI, et al. 2002. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood. 99: 912-922.
72. Wilson JT, Cui W, Sun X-L, Tucker-Burden C, Weber CJ, Chaikof EL. 2007. In vivo biocompatibility and stability of a substrate-supported polymerizable membrane-mimetic film. Biomaterials. 28: 609-617.